NGS-guided precision oncology in metastatic breast and gynecological cancer: first experiences at the CCC Munich LMU

Sultova, Elena; Westphalen, C. Benedikt; Jung, Andreas; Kumbrink, Joerg; Kirchner, Thomas; Mayr, Doris; Rudelius, Martina; Ormanns, Steffen; Heinemann, Volker; Metzeler, Klaus H.; Greif, Philipp A.; Burges, Alexander; Trillsch, Fabian; Mahner, Sven; Harbeck, Nadia und Wuerstlein, Rachel (2021): NGS-guided precision oncology in metastatic breast and gynecological cancer: first experiences at the CCC Munich LMU. In: Archives of gynecology and obstetrics, Bd. 303, Nr. 5: S. 1331-1345

Abstract

PURPOSE Comprehensive genomic profiling identifying actionable molecular alterations aims to enable personalized treatment for cancer patients. The purpose of this analysis was to retrospectively assess the impact of personalized recommendations made by a multidisciplinary tumor board (MTB) on the outcome of patients with breast or gynecological cancers, who had progressed under standard treatment. Here, first experiences of our Comprehensive Cancer Center Molecular Tumor Board are reported. METHODS All patients were part of a prospective local registry. 95 patients diagnosed with metastatic breast cancer or gynecological malignancies underwent extended molecular profiling. From May 2017 through March 2019, the MTB reviewed all clinical cases considering tumor profile and evaluated molecular alterations regarding further diagnostic and therapeutic recommendations. RESULTS 95 patients with metastatic breast or gynecological cancers were discussed in the MTB (68% breast cancer, 20% ovarian cancer, 5% cervical cancer, 3% endometrial cancer and 4% others). Genes with highest mutation rate were PIK3CA and ERBB2. Overall, 34 patients (36%) received a biomarker-based targeted therapy recommendation. Therapeutic recommendations were implemented in nine cases; four patients experienced clinical benefit with a partial response or disease stabilization lasting over 4~months. CONCLUSION In the setting of a multidisciplinary molecular tumor board, a small but clinically meaningful group of breast and gynecological cancer patients benefits from comprehensive genomic profiling. Broad and successful implementation of precision medicine is complicated by patient referral at late stage disease and limited access to targeted agents and early clinical trials. TRIAL REGISTRATION NUMBER 284-10 (03.05.2018).

• Dokumententyp: Zeitschriftenartikel
• Fakultät: Medizin
• Themengebiete: 600 Technik, Medizin, angewandte Wissenschaften > 610 Medizin und Gesundheit
• Sprache: Englisch